SS-31

SS-31 (Elamipretide) is a mitochondria-targeted tetrapeptide. The HEIVE catalog describes it as: Binds cardiolipin in the inner mitochondrial membrane; in late-stage trials for primary mitochondrial myopathy. It is also known as Elamipretide, Bendavia and MTP-131.

HEIVE groups SS-31 under mitochondrial function, oxidative stress, fatigue, energy crashes and cellular maintenance. These catalog categories are not approved indications or evidence that treatment works. See the product-specific regulatory answer below.

Yes, for a specific product and indication. Forzinity (elamipretide) received FDA accelerated approval on September 19, 2025 to improve muscle strength in adults and children with Barth syndrome weighing at least 30 kg. Continued approval may depend on confirmatory evidence. Approval of a labeled medicine does not approve an arbitrary research or compounded product containing the same ingredient.

• FDA product data (October 6, 2026)
• FDA Forzinity trial snapshot
• FDA Forzinity prescribing information

The HEIVE editorial risk summary for SS-31 lists: Injection-site reactions, reported in trials at meaningful rates. Longer-term concerns: Late-stage trials have missed primary endpoints. Efficacy itself is unresolved. This is not a complete or clinically reviewed safety assessment; risks depend on the product, route and population.

SS-31 has no single onset time established by this catalog. The editorial timeline starts with “Days 1–14”. These are illustrative model or editorial milestones, not clinically validated outcome predictions.

HEIVE's illustrative catalog entry for SS-31: 40 mg subcutaneously daily in trial settings. This is not a verified study range or a prescription. A dose cannot be transferred between products, routes or indications; use the specific approved label and the prescribing clinician's instructions where applicable.

The catalog classifies SS-31 as mainly preclinical. Its paper-count snapshot is not a live PubMed search, a count of controlled human trials or proof of safety. This FAQ has not independently validated the catalog's clinical literature claims.

The source catalog lists topical for SS-31. A listed form is not evidence of an approved or effective treatment.

Preparation of SS-31 depends on the exact labeled product. Follow its instructions for formulation, diluent, route and storage. A generic powder recipe must not be applied to a prefilled, ready-to-use or differently formulated product. The catalog's mixing example does not establish sterility or stability.

Storage for SS-31 depends on the specific formulation (injectable and topical in the source catalog). Follow the product's labeled temperature, light protection and expiry or discard instructions. A general refrigerator or 28-day rule does not establish stability or sterility for every preparation.

The HEIVE editorial summary for SS-31: Daily dosing in trial protocols; no cycling described. This summary is not a clinically validated prediction of tolerance or withdrawal for an individual.

SS-31 and MOTS-c share the catalog categories mitochondrial function, fatigue and oxidative stress. SS-31: Binds cardiolipin in the inner mitochondrial membrane; in late-stage trials for primary mitochondrial myopathy. MOTS-c: A mitochondria-encoded peptide that mimics parts of the exercise response in mice. This is a catalog comparison, not a head-to-head clinical result or a recommendation to substitute treatments.

• View MOTS-c

The HEIVE editorial summary highlights: Kidney-function markers improved in trials designed around muscle endpoints. The cited study, population and formulation must be checked before treating this summary as a clinical finding; this FAQ does not supply a verified research citation for it.